                               SEQUENCE LISTING

<110> NORTHEASTERN UNIVERSITY
 
<120> OLIGONUCLEOTIDE-POLYMER MIKTOARM CONJUGATES AND METHODS OF USE

<130> 8190.0104Z

<140> PCT/US2020/027026
<141> 2020-04-07

<150> 62/832,317
<151> 2019-04-11

<160> 12    

<170> PatentIn version 3.5

<210> 1
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"


<220>
<221> modified_base
<222> (17)..(51)
<223> An unnatural nucleotide bearing an amine group and a
      hydrophobic group, such as OH, SH, methyl and methoxy

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 1
gctattagga gtctttnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ngctattagg       60

agtctttt                                                                68


<210> 2
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"


<220>
<221> modified_base
<222> (17)..(51)
<223> An unnatural nucleotide bearing an amine group and a
      hydrophobic group, such as OH, SH, methyl and methoxy

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 2
gctattagga gtctttnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ngctattagg       60

agtctttt                                                                68


<210> 3
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 3
tttctccatg gtgctcac                                                     18


<210> 4
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 4
tttctccatg gtgctcac                                                     18


<210> 5
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 5
tttctccatg gtgctcac                                                     18


<210> 6
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 6
tttctccatg gtgctcac                                                     18


<210> 7
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 7
gtgagcacca tggag                                                        15


<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 8
ctccatggtg ctcactgcgg c                                                 21


<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 9
tttttttttt gccgcagtga gc                                                22


<210> 10
<211> 21
<212> DNA
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      target sequence"

<400> 10
gccgcagtga gcaccatgga g                                                 21


<210> 11
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 11
gactcctaat agcttttcct g                                                 21


<210> 12
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"


<220>
<221> modified_base
<222> (19)..(48)
<223> An unnatural nucleotide bearing an amine group and a
      hydrophobic group, such as OH, SH, methyl and methoxy

<220> 
<221> source
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 12
gctattagga gtctttttnn nnnnnnnnnn nnnnnnnnnn nnnnnnnntt tgctattagg       60

agtctt                                                                  66


